SI3060239T1 - Dolgodelujoči polipeptidi ter postopki za proizvodnjo in dajanje le-teh - Google Patents

Dolgodelujoči polipeptidi ter postopki za proizvodnjo in dajanje le-teh

Info

Publication number
SI3060239T1
SI3060239T1 SI201431630T SI201431630T SI3060239T1 SI 3060239 T1 SI3060239 T1 SI 3060239T1 SI 201431630 T SI201431630 T SI 201431630T SI 201431630 T SI201431630 T SI 201431630T SI 3060239 T1 SI3060239 T1 SI 3060239T1
Authority
SI
Slovenia
Prior art keywords
producing
methods
long
administering same
acting polypeptides
Prior art date
Application number
SI201431630T
Other languages
English (en)
Inventor
Fuad Fares
Udi Eyal Fima
Original Assignee
Opko Bilogics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/059,134 external-priority patent/US20140113860A1/en
Priority claimed from US14/309,496 external-priority patent/US20150038413A1/en
Application filed by Opko Bilogics Ltd filed Critical Opko Bilogics Ltd
Publication of SI3060239T1 publication Critical patent/SI3060239T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/59Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/61Growth hormone [GH], i.e. somatotropin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
SI201431630T 2013-10-21 2014-10-21 Dolgodelujoči polipeptidi ter postopki za proizvodnjo in dajanje le-teh SI3060239T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14/059,134 US20140113860A1 (en) 2006-02-03 2013-10-21 Long-acting polypeptides and methods of producing and administering same
US14/309,496 US20150038413A1 (en) 2006-02-03 2014-06-19 Long-acting polypeptides and methods of producing and administering same
EP14856666.4A EP3060239B1 (en) 2013-10-21 2014-10-21 Long-acting polypeptides and methods of producing and administering same
PCT/IL2014/050910 WO2015059695A1 (en) 2013-10-21 2014-10-21 Long-acting polypeptides and methods of producing and administering same

Publications (1)

Publication Number Publication Date
SI3060239T1 true SI3060239T1 (sl) 2020-10-30

Family

ID=52992360

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201431630T SI3060239T1 (sl) 2013-10-21 2014-10-21 Dolgodelujoči polipeptidi ter postopki za proizvodnjo in dajanje le-teh

Country Status (20)

Country Link
EP (2) EP3060239B1 (sl)
JP (3) JP6640720B2 (sl)
KR (4) KR20220130254A (sl)
CN (1) CN106163543A (sl)
AU (3) AU2014338575B2 (sl)
CA (1) CA2928269C (sl)
DK (1) DK3060239T3 (sl)
ES (1) ES2811068T3 (sl)
FR (1) FR22C1035I2 (sl)
HR (1) HRP20201114T1 (sl)
HU (2) HUE050002T2 (sl)
IL (1) IL297219B2 (sl)
MX (2) MX2016005227A (sl)
NL (1) NL301170I2 (sl)
PL (1) PL3060239T3 (sl)
PT (1) PT3060239T (sl)
RU (1) RU2746943C2 (sl)
SI (1) SI3060239T1 (sl)
TW (5) TW202317176A (sl)
WO (1) WO2015059695A1 (sl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3060239T3 (da) 2013-10-21 2020-08-03 Opko Biologics Ltd Langtidsvirkende polypeptider og fremgangsmåder til fremstilling og indgivelse heraf
JOP20190019A1 (ar) * 2016-08-30 2019-02-12 Genexine Inc تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH)
CN109942717A (zh) * 2019-04-24 2019-06-28 上海延立药业有限公司 一种长效重组人促卵泡激素及其制备方法和应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
DE3421468A1 (de) 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
DE122007000007I2 (de) 1986-04-09 2010-12-30 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
WO1989010756A1 (en) 1988-05-06 1989-11-16 Toray Industries, Inc. STABLE INTERFERON beta COMPOSITION
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
JP3045539B2 (ja) 1989-02-21 2000-05-29 ワシントン ユニバーシティ 改変型生殖ホルモン
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
WO2007092252A2 (en) * 2006-02-03 2007-08-16 Modigene Inc Long-acting polypeptides and methods of producing same
US8450269B2 (en) * 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US8946155B2 (en) * 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) * 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US8304386B2 (en) * 2006-02-03 2012-11-06 Prolor Biotech, Inc. Long-acting growth hormone and methods of producing same
US8476234B2 (en) * 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
DE102007006189B4 (de) * 2007-02-07 2009-07-30 Isotopen Technologien München AG Vorrichtung zum Befüllen eines medizinischen Instruments mit einer radioaktiven Substanz und Verfahren
DK3060239T3 (da) 2013-10-21 2020-08-03 Opko Biologics Ltd Langtidsvirkende polypeptider og fremgangsmåder til fremstilling og indgivelse heraf

Also Published As

Publication number Publication date
FR22C1035I2 (fr) 2024-02-16
KR20240110069A (ko) 2024-07-12
IL297219A (en) 2022-12-01
AU2022246472A1 (en) 2022-11-10
RU2016119565A (ru) 2018-11-02
CA2928269A1 (en) 2015-04-30
AU2020200874A1 (en) 2020-02-27
TW202120120A (zh) 2021-06-01
HUE050002T2 (hu) 2020-11-30
HUS2200014I1 (hu) 2022-05-28
RU2021110927A3 (sl) 2021-12-08
PT3060239T (pt) 2020-08-26
MX2016005227A (es) 2016-08-12
RU2746943C2 (ru) 2021-04-22
TWI720940B (zh) 2021-03-11
JP2016535015A (ja) 2016-11-10
TW201536327A (zh) 2015-10-01
RU2016119565A3 (sl) 2019-01-22
TW202317176A (zh) 2023-05-01
JP6640720B2 (ja) 2020-02-05
IL297219B1 (en) 2023-10-01
JP2022088521A (ja) 2022-06-14
PL3060239T3 (pl) 2020-11-02
HRP20201114T1 (hr) 2020-10-30
FR22C1035I1 (fr) 2022-09-09
KR102444140B1 (ko) 2022-09-15
EP3060239B1 (en) 2020-05-13
KR20160068969A (ko) 2016-06-15
JP7445695B2 (ja) 2024-03-07
NL301170I2 (nl) 2022-06-16
CA2928269C (en) 2023-03-14
AU2014338575B2 (en) 2019-11-07
AU2014338575A1 (en) 2016-06-02
ES2811068T3 (es) 2021-03-10
MX2021003908A (es) 2021-06-23
WO2015059695A1 (en) 2015-04-30
TWI777407B (zh) 2022-09-11
EP3763733A1 (en) 2021-01-13
NL301170I1 (nl) 2022-04-29
KR20220130254A (ko) 2022-09-26
IL297219B2 (en) 2024-02-01
DK3060239T3 (da) 2020-08-03
TWI720939B (zh) 2021-03-11
CN106163543A (zh) 2016-11-23
EP3060239A1 (en) 2016-08-31
TW201536313A (zh) 2015-10-01
JP7051797B2 (ja) 2022-04-11
JP2020073541A (ja) 2020-05-14
TW201536312A (zh) 2015-10-01
RU2021110927A (ru) 2021-05-21
EP3060239A4 (en) 2017-05-31
KR20210118490A (ko) 2021-09-30

Similar Documents

Publication Publication Date Title
HK1223913A1 (zh) 經取代的苯甲酰胺及其使用方法
GB2535360B (en) Methods of preparing polyhemiaminals and polyhexahydrotriazines
PL3063275T3 (pl) Terapeutyczne fuzje nukleaza-albumina i sposoby
HK1213476A1 (zh) 取代的三唑並吡啶及其使用方法
IL286759A (en) Therapeutic methods and preparations
EP2999474A4 (en) THERAPEUTIC AND METHOD OF USE
HK1209324A1 (en) Nanozymes, methods of making nanozymes, and methods of using nanozymes
HK1222129A1 (zh) 脱氧野尻霉素衍生物及其使用方法
EP3040074A4 (en) PHARMACEUTICAL PREPARATION OF INJECTION, AND METHOD OF MANUFACTURING THE SAME
HUS2200014I1 (hu) Hosszan ható polipeptidek és eljárás azok elõállítására és beadására
HK1224307A1 (zh) 原毒素- 變體及其使用方法
IL241418A0 (en) Improved methods of use for recombinant human secretoglobins
HK1202533A1 (en) Intermediates of ticagrelor and the preparation methods and for the preparation of ticagrelor
IL241290A0 (en) Subprevir polymorphs and methods for their production
GB201518061D0 (en) Method of determining degree of modified potency of bipathic medicament
GB201307082D0 (en) Pharmaceutical composition comprising 15-HETrE and methods of using the same
HK1214964A1 (zh) 製備包含治療性蛋白質的顆粒的方法
HK1213274A1 (zh) 變體因子 多肽及其產生和使用方法
PT3022251T (pt) Compósito e métodos de produção
HK1217454A1 (zh) 蛋白無針皮下注射
IL245273A0 (en) Long-acting polypeptides and methods for their preparation and administration
ZA201602304B (en) Modified anti-inflammatory proteins and method of use
EP2986309A4 (en) Peptide compounds and methods of production and use thereof
IL224391A (en) Mobile and insulated structure and method of manufacture
HUE041663T2 (hu) Myxopyronin és származékai elõállítása